Genstar inks $744M deal to buy PRA International

The private equity firm Genstar Capital has struck a deal to buy PRA International for $744 million, a premium of about 13 percent on PRA's stock price. The big CRO gets 50 days to solicit a better offer, but any new suitor would have to pay a $7.9 million break-up fee. The deal is expected to wrap in the fourth quarter.

- see this release
- here's a report on the deal from the BBC

Related Article:
PRA International Appoints Bieker as CEO. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.